Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Specific Immunotherapy With Recombinant Birch Pollen Allergen rBet v1-FV

This study has been completed.
Information provided by (Responsible Party):
Allergopharma GmbH & Co. KG Identifier:
First received: December 16, 2005
Last updated: March 1, 2013
Last verified: March 2013
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: July 2005
  Primary Completion Date: July 2004 (Final data collection date for primary outcome measure)